Company intelligence / Profile preview

Hefei Tianhui Biotechnology

Ownership: Private
Development stage: Other

Overview

Hefei Tianhui Biotechnology has completed Phase 3 clinical trials in China for its oral insulin capsule for type 2 diabetes and submitted a new drug application (NDA) to the National Medical Products Administration; marketing approval is pending. Efficacy data showed significant HbA1c reduction in key subgroups. The company has developed and advanced several recombinant insulin and GLP-1 programs, with proven commercial-scale manufacturing capabilities[7][5][1].

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small moleculeProteinRecombinant proteinPeptidesBiologic
Industry: Biotech

Drug pipeline

1 asset

insulin lisargine

Partnerships

Oramed Pharmaceuticals

Beyond the preview

Go deeper on Hefei Tianhui Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hefei Tianhui Biotechnology.